Publication:
What Do We Know About Negative Statin Trials?

dc.contributor.authorsErdogan, Okan
dc.date.accessioned2022-03-10T15:25:05Z
dc.date.accessioned2026-01-11T15:54:49Z
dc.date.available2022-03-10T15:25:05Z
dc.date.issued2010
dc.description.abstractThe benefits of statins are well Established in certain fields of cardiology. However, there are still unresolved issues in which statins are doubtfully effective in providing absolute benefit. Two large clinical trials showed that statine did not diminish the mortality rate in patients with heart failure. According to a randomized prospective clinical trial statins were also not able to halt the progression of aortic: valve sclerosis. One large trial dictated that pravastatin did not significantly reduce either all-cause mortality or coronary heart disease when compared with usual care in older participants with well-controlled hypertension and moderately elevated low density cholesterol. Ar other study revealed that in patients undergoing hemodialysis, the initiation of treatment with rosuvastatin lowered the low density cholesterol level but lad no significant effect on the composite primary end point of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke.
dc.identifier.doidoiWOS:000289660300017
dc.identifier.issn1301-3149
dc.identifier.urihttps://hdl.handle.net/11424/220098
dc.identifier.wosWOS:000289660300017
dc.language.isoeng
dc.publisherAVES YAYINCILIK, IBRAHIM KARA
dc.relation.ispartofTRAKYA UNIVERSITESI TIP FAKULTESI DERGISI
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectStatin
dc.subjectnegative
dc.subjecttrials
dc.subjectcoronary
dc.subjectaortic
dc.subjectheart failure
dc.subjectmortality
dc.subjectACUTE CORONARY SYNDROMES
dc.subjectROSUVASTATIN
dc.titleWhat Do We Know About Negative Statin Trials?
dc.typereview
dspace.entity.typePublication
oaire.citation.endPage81
oaire.citation.startPage79
oaire.citation.titleTRAKYA UNIVERSITESI TIP FAKULTESI DERGISI
oaire.citation.volume27

Files